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Neuronal circuits depend on the precise regulation of cell-surface receptors and ion channels. An
ongoing challenge in neuroscience research is deciphering the functional contribution of specific
receptors and ion channels using engineered modulators. A novel strategy, termed “tethered
toxins”, was recently developed to characterize neuronal circuits using the evolutionary derived
selectivity of venom peptide toxins and endogenous peptide ligands, such as lynx1 prototoxins.
Herein, the discovery and engineering of cell-surface tethered peptides is reviewed, with
particular attention given to their cell-autonomy, modular composition, and genetic targeting in
different model organisms. The relative ease with which tethered peptides can be engineered,
coupled with the increasing number of neuroactive venom toxins and ligand peptides being
discovered, imply a multitude of potentially innovative applications for manipulating neuronal
circuits and tissue-specific cell networks, including treatment of disorders caused by malfunction
of receptors and ion channels.
Keywords: tethered-toxins, cell-surface modulators, lynx1, receptors, ion channels

INTRODUCTION
Understanding complex processes such as neuronal activity or
cell signaling malfunctions that result in human disorders or
diseases relies on extensive knowledge about the function, structure and precision of ion channels, receptors and modulators.
As a result of this, ion channels are at present the third biggest
target class in drug discovery; yet still remain underexploited
as drug targets. Recent reviews describe the increasing interest
in peptide venom toxins for the development of drug therapies
directed towards ion channels and receptors (Blumenthal and
Seibert, 2003; Phui Yee et al., 2004; Lynch et al., 2006; Han et al.,
2008; Twede et al., 2009). Specific areas in which peptide toxins
have demonstrated their potential include Alzheimer’s disease
(candoxin) (Nirthanan et al., 2002), chronic pain (MVIIA)
(Miljanich, 2004) and myasthenic autoimmune response (αBgtx) (Drachman, 1981; Mebs, 1989). For instance, snake neurotoxins bind to nicotinic acetylcholine receptors (nAChRs) with
affinities within the pico and nanomolar range (Chiappinelli,
1991), which indicates that these would be among the best probes
for investigating potential therapeutics that affect nAChR activity. The unique homologies of endogenous lynx1 prototoxins
with venom toxins provided a biological scaffold for developing
recombinant molecules to selectively modulate ion channels and
receptors. Thus, based on the characteristics and mode of action
of lynx1 cell-surface modulators, new classes of “tethered toxins”
and “tethered ligands” were created as probes to characterize ion
channels and receptors (Ibañez-Tallon et al., 2004; Fortin et al.,
2009; Auer et al., 2009; Stürzebecher et al., 2009). Tethering peptide toxins or ligands close to their point of activity in the cell
plasma membrane provides a new approach to the study of cell
networks and neuronal circuits, as it allows selective targeting
of specific cell populations, enhances the working concentration
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of the ligand or blocker peptide, and permits the engineering of
a large variety of t-peptides (e.g., including use of fluorescent
markers, viral vectors and point mutation variants).
This focused review describes the identification of lynx-1
and related endogenous cell surface modulators, the development of the t-peptide technology, and the application of the
t-peptide strategy to basic research, cell-based therapies, and
drug discovery.

ENDOGENOUS CELL-SURFACE MODULATORS OF
LIGAND-GATED ION CHANNELS: THE LY6 SUPERFAMILY
Cell-surface receptors and ion channels are modulated by a rich
variety of peptide neurotransmitters, hormones and ligands, but
there are few examples of membrane-anchored modulators in
nature. The Ly6 superfamily which includes lynx1-and slurp1 cholinergic modulators, elapid snake venom toxins, and Ly6
molecules of the immune system, constitutes a unique class of
short proteins that are either tethered to the cell surface via a
glycosylphosphatidylinositol (GPI) anchor, like lynx1, or secreted
as venom toxins (Figure 1). Members of this superfamily share
the characteristic 8–10 cysteine motif that determines their compact three-finger structure. Examples of the GPI-anchor subgroup include molecules of the immune system such as CD59
(Davies et al., 1989), ly6A-E (Rock et al., 1989), ly6G (Mallya
et al., 2006), and ly6K (de Nooij-van Dalen et al., 2003), the neuronal proteins lypd6 (Darvas et al., 2009), ly6H (Dessaud et al.,
2006) and the urokinase plasminogen activator receptor (uPAR)
(Blasi and Carmeliet, 2002). Members lacking the GPI-anchor
comprise the cholinergic modulators SLURP-1 (Adermann
et al., 1999; Chimienti et al., 2003) and SLURP-2 (Tsuji et al.,
2003), cobra toxins, and other three finger venom toxins (Tsetlin,
1999) (Figure 1).
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FIGURE 1 | Schematic representation of Ly-6/uPAR channel modifiers and
engineered tethered toxins (t-toxins). (A) Examples of the Ly-6/uPAR
superfamily include soluble Slurp-1, snake α-bungarotoxin (αBgtx) and the GPIanchored cell-membrane bound lynx1. The schematic below the drawing of the
channel indicates the coding sequences associated with lynx1, namely an Nterminal secretory signal region, followed by the amino acid residues that
correspond to the lynx1 peptide, and a C-terminal GPI anchor. (B) The structural

ALLOSTERIC MODULATION OF NACHRS BY Ly6 SUPERFAMILY
MOLECULES

Ly6 SPECIES DIVERSITY

Lynx1 was the first identified member of the Ly6 superfamily
capable of cell-surface modulatory action on a neurotransmitter
receptor (Miwa et al., 1999). Lynx1 assembles and colocalizes with
nAChR in the brain (Ibañez-Tallon et al., 2002) and in the lung
(Sekhon et al., 2005). nAChRs stably associated with lynx1 are less
sensitive to their ligand agonists acetylcholine and nicotine, display
more rapid desensitization, and show a shift in the distribution of
channel openings toward a faster inactivating species with more
uniform, larger amplitude currents (Ibañez-Tallon et al., 2002).
These findings, along with studies showing enhanced nicotinemediated calcium influx and synaptic efficacy in lynx1 null mutant
mice, are strong indicators that lynx1 is an allosteric modulator of
nAChR function in vivo (Miwa et al., 2006). Other lynx-like molecules recently identified have similar properties. Lynx2 and ly6H,
which are GPI-anchored to the cell membrane, have been localized
to central and peripheral neurons in mice (Dessaud et al., 2006).
Functional studies demonstrate that lynx2, but not ly6H, changes
the agonist sensitivity and desensitization properties of nAChRs
through direct association (Tekinay et al., 2009). Consistent with
lynx2 enrichment in neurons that participate in circuits controlling fear and anxiety, lynx2 null mice display increased anxietylike behaviors due to enhanced nAChR activity (Tekinay et al.,
2009). Recently, a third allosteric modulator of nAChRs, named
lypd6, has been identified in central neurons. Lypd6 is cell-membrane bound and selectively increases the calcium conductance of
nAChRs (Darvas et al., 2009). The lynx1-related secreted ligands
SLURP-1 and SLURP-2, also act as neuromodulators of nAChRs
and have been linked to skin disorders (Chimienti et al., 2003;
Arredondo et al., 2006).
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homology of lynx1 with αBgtx gave rise to the tethered-peptide strategy of
using the biological scaffold of lynx1 (secretory signal and GPI signal) to
generate recombinant membrane-bound toxins and peptide ligands such as the
illustrated t-αBgtx. The schematic below the drawing of the channel indicates
the coding regions that were conserved from lynx1 (shown in A), and those that
were altered to accommodate the αBgtx (the toxins sequence, flag tag, and
linker regions).

Lynx1-like molecules are well conserved across species, both in
structure and function, suggesting the importance of cell-surface modulators of nicotinic receptors in nature. Examples of
Ly6 superfamily species diversity include molecules found in C.
elegans (Odr-2; Chou et al., 2001), fireflies (Pr-lynx1; Choo et al.,
2008), Drosophila (Hijazi et al., 2009) and chicken (recently identified prostate stem cell antigen PSCA; Hruska et al., 2009). Prlynx1 and PSCA are of particular importance as Pr-lynx1 is the
first modulator of nAChRs in an insect species (Choo et al., 2008),
and PSCA appears to prevent programmed cell death of neurons by
antagonizing nAChRs (Hruska et al., 2009). The lynx1-like family
of allosteric modulators of nAChRs constitutes a unique example
of cell-surface channel modifiers that have evolved for fine-tuning
of neurotransmitter receptor function in vivo.

VENOM PEPTIDE TOXINS: SPECIFIC MODULATORS OF ION
CHANNELS AND RECEPTORS
Venom peptide toxins from predatory organisms such as scorpions, snakes and marine cone snails are suitable as agents for use
in engineering cell-type specific modulators. Neurotoxins isolated
from animal venom are disulfide-rich peptides that have been used
extensively to characterize the structure–activity relationships of
specific ion channels (ligand or voltage-gated) and cell-surface
receptors (Catterall, 1986; Tsetlin, 1999; Norton and Olivera,
2006). α-bungarotoxin and other α-neurotoxins from Elapidae
and Hydrophidae snakes were used to provide the first identification of nAChRs (Endo and Tamiya, 1991; Hucho et al., 1996;
Léna and Changeux, 1998). Similarly, α- and β-neurotoxins from
scorpions have been broadly used to modify voltage-gated sodium
channels (VGSC or Navs) by delaying inactivation (α) or shifting the
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membrane potential dependence (β) (Zuo and Ji, 2004; Bosmans
and Tytgat, 2007). Neuropeptides from venomous marine cone
snails (conotoxins) are prolific in their range and specificity for targeting various ion channels and receptors (Terlau and Olivera, 2004;
Gowd et al., 2008; Han et al., 2009). As shown in Table 1, venom
peptide toxins modulate a wide range of molecular targets. Peptide
toxins vary in length from 12–30 residues in cone snails to 40–80
residues in toxins from scorpions and snakes. The relatively small
size of these polypeptides, coupled with their structural integrity
imposed by numerous disulfide bonds, have facilitated their use for
investigating ion channels and receptors (Fontecilla-Camps et al.,
1988; Pashkov et al., 1988; Tsetlin, 1999; Zhang et al., 2006).

scorpion venoms (Possani et al., 1999; Phui Yee et al., 2004) or
two to three disulfide bridges in cone snail toxins (Sine et al.,
1995; McIntosh et al., 1999; Ellison et al., 2006). α-neurotoxins
that target nAChRs include α-Bgtx, MII and BuIA (Table 1),
while other α-neurotoxins slow the sodium current inactivation
in excitable membranes (Couraud et al., 1982). δ-Conotoxins,
such as δ-SVIE, which bind to Navs also cause a delayed inactivation of sodium currents (Bulaj et al., 2001). They share a cysteine
framework with the structure C-C-CC-C-C, that is identical to
that of µO-conotoxins, like MrVIA and MrVIB which inhibit
Nav1.2, Nav1.4 and Nav1.8 (Terlau et al., 1996; Daly et al., 2004;
Bulaj et al., 2006). µ-Conotoxins contain a framework of CC-CC-CC and are by far the best characterized of all the conotoxins
that target Navs. Several µ-conotoxins such as PIIIA, SmIIIA, and
potentially BuIIIA, inhibit Navs in a similar manner to tetrodotoxin (TTX), by binding to site I on the channel (Catterall, 2000;
Goldin, 2001). Despite the ever growing number of discovered
natural toxins, only a few κ-conotoxins have been characterized so

PEPTIDE TOXINS SPECIFIC FOR nAChR AND VOLTAGE-GATED
ION CHANNELS

α-Neuropeptides, which target nAChRs compete with cholinergic agonists and antagonists (Endo and Tamiya, 1991) and
are characterized by four to five disulfide bridges in snake and

Table 1 | Examples of venom peptide toxins used for generation of tethered modulators and corresponding targeted receptors/ion channels.
Tethered

Origin

Length

toxin
AgaIIIA

Agelenopsis aperta (funnel web spider)

AgaIVA
APETx2

Ion channel/receptor specificity

Original reference

76

VGCC: Cav2.2 (N-type), Cav1 (L-type)

Mintz et al. (1991)

48

VGCC: Cav2.1 (P/Q-type)

Mintz et al. (1992)

42

homomeric ASIC3 > heteromeric

Diochot et al. (2004)

(aa)

Anthopleura elegantissima (aggregating anemone)

ASIC3-ASIC2b
α-AuIB

Conus aulicus (guilded cone snail)

15

nAChR: α3β4 >> α2β2

Luo et al. (1998)

α-Bgtx

Bungarus multicinctus (multi-banded krait)

74

nAChR: α7, α1β1δγ/ε, α3β2

Chang and Lee (1963),
Nirthanan and Gwee
(2004)

κ-Bgtx
µ-BuIIIA, B, C

nAChR: α3β2, α7, α4β2

Chiappinelli (1983)

26

VGSC: Nav1.4

Holford et al. (2009)

13

nAChR: α6β2 > α3β2 >

Azam et al. (2005)

66
Conus bullatus (bubble cone snail)

α-BuIA

α2β2 > α4β2
α-GID

Conus geographus (geography cone snail)

19

nAChR: α7 = α3β2 > α4β2, α3β4

Nicke et al. (2003)

HntxIII

Haplopelma hainanum

35

VGSC: DRG Nav TTX-S

Xiao and Liang (2003)

HntxIV

(Chinese giant black earth tiger)

35

VGSC: DRG Nav TTX-S

Xiao and Liang (2003)

Kurtoxin

Parabuthus transvaalicus (South African

63

VGCC: Cav3 (T-type), Cav2.1

Chuang et al. (1998)

fattail scorpion)
α-MI

(P/Q-type)

Conus magus (Magician’s cone snail)

α-MII

14

nAChR: α1β1δε >> α1β1δγ

McIntosh et al. (1982)

16

nAChR: α6/α3β2 > α3β2 >

Cartier et al. (1996)

α3β4 = α4β2
ω-MVIIA

25

VGCC: Cav2.2 (N-type)

Bowersox and

ω-MVIIC

26

VGCC: Cav2.1 (P/Q-type),

Hillyard et al. (1992)

Luther (1998)
Cav2.2 (N-type)
µO-MrVIA

Conus marmoreus (marbled cone snail)

31

VGSC: Nav 1.2, 1.4, 1.8

McIntosh et al. (1995)

µ-PIIIA

Conus purpurascens (purple cone snail)

22

VGSC: Nav 1.2

Shon et al. (1998)

27

VGKC: Kv1 shaker channel

Terlau et al. (1996)

κ-PVIIA
α-PnIB

Conus pennaceus (penniform cone snail)

16

nAChR: α7 > α3β2

Fainzilber et al. (1994)

α-RgIA

Conus regius (crown cone snail)

12

nAChR: α9α10 >>> α7

Ellison et al. (2006)

κM-RIIIK

Conus radiatus (rayed cone snail)

24

VGKC: Kv1 shaker channel

Ferber et al. (2003)

µ-SmIIIA

Conus stercusmuscarum (fly-specked cone snail)

30

VGSC: Nav 1.8

West et al. (2002)

SNX482

Hysterocrates gigas (Cameroon red baboon spider)

41

VGSC: Cav2.3 (R-type)

Newcomb et al.

Conus striatus (striated cone snail)

31

VGSC: Nav 1.4 > Nav 1.2

Lu et al. (1999)

(1998)
δ-SVIE
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far. κ-conotoxins bind to voltage-dependent potassium channels
(VGKC or Kv) altering either the repolarization phase of action
potentials or the resting membrane potential. The most commonly identified κ-conotoxin is PVIIA, which blocks Shaker K
channels cloned from Drosophila (Naranjo, 2002). Other gating
modifiers of Kv channels are the phrixotoxins (PaurTX) I and II
(Bosmans et al., 2006). Blockers of voltage-gated calcium channels
(VGCC or Cav) include agatoxin IIIA and IVA. The most prominent VGCC toxin antagonist is conotoxin MVIIA, a highly specific
blocker of N-type calcium channels which has been developed as
an analgesic for the treatment of chronic pain (Miljanich, 2004;
Staats et al., 2004).
The high degree of specificity with which venom peptide
toxins bind to voltage and ligand gated sodium (Nav), calcium
(Cav), and potassium (Kv) ion channels, and receptors such as
nAChRs, N-methyl-d-aspartate and G-protein coupled receptors (GPCRs), make them ideal for deciphering the connections
between cell types, and for reversibly manipulating the activity of
selective cell subtypes.

ENGINEERING TETHERED PEPTIDES FOR CELL-SURFACE
MANIPULATIONS OF RECEPTORS AND ION CHANNELS
The unique functionality of endogenous lynx1-like cell-surface
modulators provides a framework to use peptide toxins from
predatory animals to manipulate ion channels and receptors in a
novel manner. Peptide toxins that have been routinely employed

FIGURE 2 | Modular architecture of membrane-tethered toxin and ligand
peptides. (A) Illustration of tethered-peptide variants consisting of secretory
pathway signal sequence (ss), toxin/ligand cassettes, fluorescence markers
(EGFP or mCherry), epitopes for immunostaining (Flag-tag, Myc-tag), flexible
linker regions, and distinct functional modules for membrane attachment (GPIsignal, transmembrane-domain TM). (B) Illustration of t-toxin carrying the
nAChR-specific snail-toxin GID with varying linker lengths [short (s), 1L, 2L and
3L]. (C) Electrophysiological recordings in Xenopus laevis oocytes expressing α7
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for neuroscience research do not normally exist as cell-surface
anchored molecules. Using the scaffold of the lynx1-like gene
family, i.e., secretory signal and consensus sequences for GPI
processing and recognition, it is possible to produce a series
of tethered toxins (t-toxins) that are highly effective modifiers
of neuronal activity (Ibañez-Tallon et al., 2004). This design
directs any bioactive peptide to the secretory pathway, where
the signal sequence is cleaved and the GPI targeting sequence
is substituted by a covalent bond to GPI, anchoring the peptide
to the extracellular side of the plasma membrane of the cell
in which it is expressed (Figure 1B). Recombinant t-peptides
have a modular framework consisting of a secretion signal, linkers, epitopes and/or fluorescent markers and membrane tethers
(Figures 1B and 2A). The GPI-anchor targeting motif can be
replaced with transmembrane (TM) domains fused with fluorescent marker genes (Figures 2A,B) (Auer et al., 2009). So far,
approximately 40 different chimeric t-toxins derived from the
venom of several predatory animals have been cloned and their
activity has been characterized on voltage and ligand-gated ion
channels (Table 1) (Ibañez-Tallon et al., 2004; Hruska et al.,
2007; Wu et al., 2008; Stürzebecher et al., 2009; Auer et al., 2009).
Furthermore, the t-peptide strategy has also been successfully
extended to other bioactive peptides, such as ligand peptides for
constitutive activation of GPCRs (Choi et al., 2009; Fortin et al.,
2009), illustrating the general applicability of this approach for
cell-surface modulation of receptors.

nAChR alone (control) or together with tethered-GID (t-GID) with increasing
linker lengths. t-GID expression results in complete block of nicotine-induced α7
nAChR current for short (6 aa, GIDs-TM) and long (20 aa, GID1L-TM) linker
variants, while longer linkers (GID2L-TM and GID3L-TM, 40 aa and 60 aa) lead to
decreased blocking capability. Number of recorded cells displayed in/above
columns. (D) Representative traces of electrophysiological recordings in (C)
suggest an optimal distance of the GID peptide from the plasma membrane of
9–22 aa to achieve complete inhibition of α7 nAChR.

www.frontiersin.org

October 2009 | Volume 2 | Article 21 | 4

Holford et al.

Neuronal regulation using tethered peptides

COMPONENTS CRITICAL TO T-PEPTIDE SYNTHESIS

The biological activity of each tethered construct has to be individually evaluated and optimized per receptor/channel combination.
While anyone with knowledge of cloning technology can construct
a tethered-peptide, some forethought is required depending on how
the t-peptide will be implemented. This is due to several factors
including variability in the nature of the bioactive peptide and ion
channel or receptor being targeted, and in the constraints imposed
by the modular architecture of the tethers, linkers and epitope-tags.
The vast amount of modular choices available for constructing
tethered toxins point to its broad appeal and indicate the feasibility
of tailor-made tethered manipulators for a wide range of different
receptors/channels.
Amino acid composition of the bioactive peptide

Expression and functional assays have revealed that several elements
are critical to achieve robust expression on the cell-surface and rotational flexibility for correct modulation of the t-toxin/peptide to the
receptor or channel of interest. The affinity of the bioactive peptide
for its cognate ion channel or receptor has to be taken into account.
Toxins with a strong affinity are potentially more effective. It is
also important to consider the composition and length of the peptides to be tethered, i.e., charges and hydrophobicity of the amino
acid residues, number of cysteine bonds in the case of toxins, and
existence of non-canonical residues, or terminal amidations. For
example, substitution of hydroxylated or carboxylated amino acids
with non-modified residues in highly post-translationally modified
conotoxins, such as GVIA (Olivera et al., 1984), RIIIK (Ferber et al.,
2003), PIIIA (Shon et al., 1998) and GID (Nicke et al., 2003), failed
to yield satisfactory activity in their tethered constructs, except in
the case of GID (see Figures 2C,D). Most likely these variations
in efficacy are dependent on the location of the posttranslational
modification in the toxin sequence. In general, the makeup of the
peptide or toxin to be tethered has to be taken into account, but
it is not predictive of the expression and activity of its tethered
form. MrVIA and MrVIB, which despite their high hydrophobicity content and difficulties to be chemically synthesized (Terlau
et al., 1996; Bulaj et al., 2006), are well expressed at the cell-membrane, and functionally active when tethered (Ibañez-Tallon et al.,
2004; Wu et al., 2008; Stürzebecher et al., 2009). Other examples
are the tethered forms of α- and κ-bungarotoxins which were well
expressed and functionally competent (Ibañez-Tallon et al., 2004;
Hruska et al., 2007) despite being long peptides (68–82 aa), while
shorter conotoxins such as SmIIIA (30aa) or MVIIC (26aa) were
not heterologously expressed, possibly due to folding disturbances
or high proportion of charged amino acids.
Distance of the linker region

Another relevant feature when designing t-peptide constructs is
the linker sequence bridging the toxin peptide to the GPI anchor
or TM domain (Figures 2A,B). The distance of the t-toxin or tpeptide from the cell-surface has to be tailor-made for individual
receptors and channels, and can be used for mapping active binding
sites. Tethered constructs have been cloned using linkers consisting
of glycine–asparagine repeats with lengths varying from 6 amino
acids (short) to 20 amino acids (long), 40aa (2× long) or 60 aa (3×
long) (Figure 2B) (Ibañez-Tallon et al., 2004). The longer flexible
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linker provides rotational freedom for the t-toxin to bind within
the vestibule of voltage-gated channels (Ibañez-Tallon et al., 2004),
or for ligand peptides to reach their binding site, such as onto class
B1 GPCRs (Fortin et al., 2009). Experiments varying the length
of the linker region of t-GID conotoxin indicate that a linker is
necessary for inactivation of α7 nAChR currents. However, when
the linker exceeds a certain length the inactivation is incomplete
(Figures 2B–D). Similarly, the tethered form of the neuropeptide
pigment dispersing factor (t-PDF) requires a short linker for effective binding to its receptor (Choi et al., 2009).
Choice of membrane tether: GPI vs. TM

The choice of membrane tether depends on the characteristics of
the peptide as well as on the epitope-tags and markers to be used
in combination (Figures 1B and 2A,B). GPI anchors, which are less
bulky than TM domains, may facilitate the mobility of the t-peptide
in close proximity to its receptor within the plasma membrane. If
the toxin or peptide does not require a free N-terminus for interacting with its cognate receptor, GPI versions containing EGFP followed by the t-toxin may be used (Figure 2). However, GPI anchors
are susceptible to cleavage by endogenous phospholipases, such as
PI-PLC and phospholipase D (Paulick and Bertozzi, 2008). This has
been suggested as a mechanism used by cells for selective and rapid
release of certain GPI-anchored proteins at specific times. To avoid
this potential problem, the GPI anchor can be replaced with a TM
domain in t-toxins (Figure 2). TM domains can be used to retain
t-peptides at the cell-surface and link fluorescent markers to the
cytoplasmatic side of the plasma membrane avoiding hindrances
between them.

CELL-SPECIFIC TARGETING AND CELL-AUTONOMOUS
REGULATION IN MODEL ORGANISMS
Tethered toxins and peptides can be used for very diverse applications pertaining to experimental animal physiology. Because of
their mode of action at the cell-surface, membrane-anchored peptide molecules act only on ion channels and receptors present in the
membrane of the cell that is expressing the t-toxin or t-peptide, and
not on identical receptors present on neighboring cells that do not
express the tethered construct (Ibañez-Tallon et al., 2004). Several
studies have shown that recombinant toxins as well as peptide ligands are not dispersed in solution and retain their high specificity
for their cognate receptors, indicating that this approach can be
used to restrict the site of neurotoxin or peptide ligand action to
genetically targeted cells. For example, in vivo transgenic delivery of
t-αBgtx in zebrafish using a muscle cell-specific promoter results in
blockade of nAChR currents in muscle cells that express t-αBgtx but
not in adjacent muscle fibers or in cells that express t-κBgtx, which
has no activity on muscle-nAChRs (Ibañez-Tallon et al., 2004).
Similarly, experiments in chicken employing a viral system to transduce ciliary neurons have revealed that expression of t-αBgtx blocks
calcium currents via nAChRs and prevents programmed cell-death
of these neurons during early development (Hruska et al., 2007).
Further in vivo applications of the tethered toxin strategy have
been carried out using transgenesis in Drosophila melanogaster.
These studies have shown that cell-specific expression of the sodium
channel toxin δ-ACTX-Hv1a in pacemaker clock neurons induces
arrhythmicity (Wu et al., 2008). Transgenic targeting of the same
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clock neurons with a tethered form of the PDF neuropeptide, which
is normally rhythmically secreted by these neurons, constitutively
activates its cognate GPCR, interfering with circadian control circuit (Choi et al., 2009). These examples illustrate the possibilities for
cell-specific targeting and cell-autonomous regulation of channels
and receptors with genetically encoded tethered toxins. As venom
toxins are established tools for dissecting ionic currents in many
animal species, the tethered-toxin strategy allows cell specific functional analysis of ion channels and receptors in model organisms
(e.g., zebrafish, flies, rats, large mammals) for which transgenic
methodologies are commonly used but gene targeting strategies
are yet not available.

APPLICATIONS AND PERSPECTIVE USE OF CELL-SURFACE
PEPTIDES TO BASIC RESEARCH, CELL-BASED THERAPIES
AND DRUG DISCOVERY
Ion channels and receptors are involved in every physiological action from breathing to heart beating. Understanding the
mechanics and functional activity of these macromolecular
complexes is a grand challenge in science. The tethered-peptide
method is one tool that has the potential to tackle certain aspects

FIGURE 3 | Applications of the tethered-peptide strategy. Endogenous
peptide ligands, natural toxins, and synthetic, modified versions of ligands or
toxins can be integrated into recombinant membrane-attached fusion constructs
and applied in vitro in transfected or transduced cells in cell-culture, or in vivo in
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of this challenge, particularly in the area of cell-specific modulators (Figure 3). Genetically encoded cell-surface modulators can
be adapted to a wide range of applications due to their small
size, amenability to point mutagenesis, and relative ease to be
combined with fluorescent markers, viral and transgenic vectors,
Cre-dependent and transcriptional-control elements, and subcellular targeting motifs. Inhibition or constitutive activation of
ion channels and receptors can be attained in a cell-type specific
manner depending on the selectivity of the neuroactive peptide
or hormone.
NEURONAL CIRCUITS: DISSECTING INDIVIDUAL IONIC CURRENTS

Manipulation of ion channels in specific neuronal populations within living animals can be achieved by transgenesis
(Ibanez-Tallon et al., 2004; Wu et al., 2008). Similarly, viral
methods can be employed to characterize the cellular functions
mediated by specific ionic currents inactivated by delivery of
t-toxins (Hruska et al., 2007). Gene knockouts led to a wide
range of studies to characterize the function of receptors and
ion channels (Capecchi, 2005). However, many receptors consist of multimeric assemblies of components, with common

transgenic or virus-transduced animals. The t-peptide retains the specificity of
the toxin/peptide ligand allowing controlled manipulation of distinct subtypes of
ion channels and receptors in a given neuronal circuit without affecting other
channels/receptors in the cell.
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components frequently shared by functionally diverse receptor
types, modifying any one gene can potentially compromise the
function of every complex with which it is associated. For example, it has proven difficult to separate the contribution of Cav2.1
and Cav2.2 VGCC channels by targeted deletion of one or the
other alpha subunits because of functional compensation of ionic
currents (Inchauspe et al., 2004; Takahashi et al., 2004). As venom
toxins inactivate specific ionic currents produced by a receptor
or channel complex, the t-toxin strategy could be an alternative
to prevent compensatory ionic currents that may occur upon
gene-deletion of receptor subunits.
The cell-autonomous modulatory action of tethered peptides
and their selectivity for cognate cell-surface molecules can be
further exploited by directing t-peptide molecules to subcellular
compartments within the neuron (Figure 3). For instance, t-toxins could be directed to the axon initial segment where sodium
channels are concentrated (Garrido et al., 2003), or to the dendritic compartment (Lewis et al., 2009). Further modifications of a
number of optimized and novel tethered toxins for in vivo use will
offer new possibilities for investigations regarding the physiology
of neuronal circuits.
CHANNELOPATHIES AND OTHER DISEASES

The tethered-peptide strategy represents a potential new avenue
for the development of genetic therapies for chronic diseases
caused by malfunction of ion channels and peptide ligand receptors. Several human disorders that affect nervous system functions
have been traced to mutations in genes encoding ion channels
or regulatory proteins (George, 2005). These disorders, referred
to as channelopathies, can be targeted by the tethered-peptide
strategy when the disorder results in hyperactivity of the channel. Examples of hyperactive disorders include gain-of-function
mutations in P/Q-type calcium channels, linked to familial hemiplegic migraine type 1 (Ophoff et al., 1996; Tottene et al., 2009), or
mutations in neuronal nAChRs associated to autosomal dominant
nocturnal frontal lobe epilepsy (Steinlein et al., 1995; Klaassen
et al., 2006). One potential application would be to genetically
introduce t-toxins into the corresponding mouse mutant models
in a cell-specific manner to dissect the circuitry of the disease
(Figure 3). Conversely, activation of receptors with t-peptide
ligands could be beneficial to control GPCRs in a cell-selective
manner (Figure 3). For instance, isoforms of glucagon-like and
calcitonin-gene-related peptides are presently being used to regulate insulin release and bone remodeling in diabetes (Green and
Flatt, 2007) and osteoporosis (Hoare, 2005). Similarly, feedingregulation neuropeptides such as orexin or ghrelin (Shioda et al.,
2008) could be targeted to circuits involved in appetite control, or
tethered opioid peptides could be directed to nociceptive neurons.
With an ever-growing interest in identifying the potential of naturally occurring venom peptide toxins (Blumenthal and Seibert,
2003; Han et al., 2008; Twede et al., 2009), as well as novel ligands for orphan GPCRs encrypted in the human proteome (Jiang
and Zhou, 2006; Shemesh et al., 2008), an increasing number of
peptide based therapies could be possible. Furthermore, parallel
development on the safety of viral methods for genetic intervention will increase the number of diseases to which the t-peptide
strategy is applicable.
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IMPLICATIONS OF TETHERED PEPTIDES FOR DRUG DISCOVERY

Ion channels and GPCRs are some of the biggest molecular drug
targets yet presently remain underexploited in drug discovery
efforts. Peptide toxins, which are highly effective modulators of
ion channels and GPCRs, offer an intriguing opportunity for
increasing the drug development pipeline. Specific areas in which
peptide toxins have demonstrated their potential include chronic
pain (Miljanich, 2004) and myasthenic autoimmune response
(Drachman, 1981). A major drawback to the universal usage of
peptide toxins in the development of therapeutics has been the
scarcity of obtaining the venom product. To circumvent this, most
toxins are synthesized chemically, but this too has significant problems, one being obtaining the correct disulfide scaffold with in
vitro folding. To combat these synthesis hurdles several structural
strategies and characterization methods have been developed
(Munson and Barany, 1993; Cuthbertson and Indrevoll, 2000;
Han et al., 2009; Ueberheide et al., 2009; Walewska et al., 2009).
However, even when the toxin is successfully synthesized, soluble
toxins cannot be directed to single cell populations, are expensive,
and have a limited time of application that makes their use in vivo
problematic. The t-peptide strategy surmounts these limitations
with the ability to recombinantly synthesize the toxins or peptide
ligands in the cell itself, and co-express it with the molecular
target (receptor or channel) to be screened. Such a cell-surface
peptide tethering strategy can readily introduce point mutations
to interconvert tethered agonists into antagonists. Several recent
reports use the t-peptide technology to characterize point mutants
of peptide hormones against class B1 GPCRs (Ibañez-Tallon et al.,
2004; Fortin et al., 2009). In a similar manner, the t-peptide technology could be applied to screen gene libraries of t-peptides
against specific membrane proteins by co-expression in the same
cell. T-peptides with activating or blocking capabilities could be
monitored with functional assays, i.e., calcium influx. This type of
screen could be beneficial to block channels that are hyperactive
in certain diseases, such as TRPP2, for which no natural toxins
have yet been identified. These features make the t-peptide genetic
approach a promising strategy for drug discovery and development of targeted therapeutics.

SUMMARY
The t-peptide strategy is an innovative technique for manipulating
neuronal circuits in order to dissect the specific biological roles of
ion channels and cell-surface receptors both in vitro and in vivo.
The studies presented here illustrate how the t-peptide approach
can be used to increase cellular specificity of neuropeptides by
restricting their actions to targeted cell types through membrane
tethering. The t-peptide method is relatively easy to implement
and has the potential to significantly impact neuroscience research
and cell-based drug screening of membrane proteins for targeted
therapeutics.

ACKNOWLEDGMENTS
This work was supported by the Helmholtz Gemeinschaft, and SFB
665. Mandë Holford acknowledges support from the Chemistry
Division and Office of International Science and Engineering at
the NSF (CHE 0610202).

www.frontiersin.org

October 2009 | Volume 2 | Article 21 | 7

Holford et al.

REFERENCES
Adermann, K., Wattler, F., Wattler, S.,
Heine, G., Meyer, M., Forssmann, W.
G., and Nehls, M. (1999). Structural
and phylogenetic characterization of
human SLURP-1, the first secreted
mammalian member of the Ly-6/
uPAR protein superfamily. Protein
Sci. 8, 810–819.
Arredondo, J., Chernyavsky, A. I.,
Jolkovsky, D. L., Webber, R. J., and
Grando, S. A. (2006). SLURP-2: a
novel cholinergic signaling peptide in
human mucocutaneous epithelium.
J. Cell. Physiol. 208, 238–245.
Azam, L., Dowell, C., Watkins, M.,
Stitzel, J. A., Olivera, B. M., and
McIntosh, J. M. (2005). {alpha}Conotoxin BuIA, a novel peptide from
Conus bullatus, distinguishes among
neuronal nicotinic acetylcholine
receptors. J. Biol. Chem. 280, 80–87.
Blasi, F., and Carmeliet, P. (2002). uPAR:
a versatile signalling orchestrator. Nat.
Rev. Mol. Cell Biol. 3, 932–943.
Blumenthal, K. M., and Seibert, A. L.
(2003). Voltage-gated sodium channel toxins: poisons, probes, and future
promise. Cell Biochem. Biophys. 38,
215–238.
Bosmans, F., Rash, L., Zhu, S., Diochot, S.,
Lazdunski, M., Escoubas, P., and
Tytgat, J. (2006). Four novel tarantula
toxins as selective modulators of voltage-gated sodium channel subtypes.
Mol. Pharmacol. 69, 419–429.
Bosmans, F., and Tytgat, J. (2007). Voltagegated sodium channel modulation
by scorpion alpha-toxins. Toxicon 49,
142–158.
Bowersox, S. S., and Luther, R. (1998).
Pharmacotherapeutic potential of
omega-conotoxin MVIIA (SNX-111),
an N-type neuronal calcium channel
blocker found in the venom of Conus
magus. Toxicon 36, 1651–1658.
Bulaj, G., DeLaCruz, R., AzimiZonooz, A., West, P., Watkins, M.,
Yoshikami, D., and Olivera, B. M.
(2001). δ-Conotoxin structure/function through a cladistic analysis.
Biochemistry 40, 13201–13208.
Bulaj, G., Zhang, M., Green, B. R.,
Fiedler, B., Layer, R. T., Wei, S.,
Nielsen, J. S., Low, S. J., Klein, B. D.,
Wagstaff, J. D., Chicoine, L., Harty,
T. P., Terlau, H., Yoshikami, D., and
Olivera, B. M. (2006). Synthetic µOconotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and
has a long-lasting analgesic activity.
Biochemistry 45, 7404–7414.
Capecchi, M. R. (2005). Gene targeting in
mice: functional analysis of the mammalian genome for the twenty-first
century. Nat. Rev. Genet. 6, 507–512.
Cartier, G. E., Yoshikami, D., Gray, W. R.,
Luo, S., Olivera, B. M., and

Frontiers in Molecular Neuroscience

Neuronal regulation using tethered peptides

McIntosh, J. M. (1996). A new alphaconotoxin which targets alpha3beta2
nicotinic acetylcholine receptors.
J. Biol. Chem. 271, 7522–7528.
Catterall, W. A. (1986). Molecular properties of voltage-sensitive sodium
channels. Annu. Rev. Biochem. 55,
953–985.
Catterall, W. A. (2000). From ionic currents to molecular mechanisms: the
structure and function of voltagegated sodium channels. Neuron 26,
13–25.
Chang, C. C., and Lee, C. Y. (1963).
Isolation of neurotoxins from the
venom of Bungarus multicinctus and
their modes of neuromuscular blocking action. Arch. Int. Pharmacodyn.
Ther. 144, 241–257.
Chiappinelli, V. A. (1983). Kappa-bungarotoxin: a probe for the neuronal
nicotinic receptor in the avian ciliary
ganglion. Brain Res. 277, 9–22.
Chiappinelli, V. A. (1991). K-neurotoxins and α-neurotoxins: effects
on neuronal nicotinic acetylcholine receptors. In Snake Toxins, A.
L. Harvey, ed. New York, Pergamon
Press, pp. 223–258.
Chimienti, F., Hogg, R. C., Plantard, L.,
Lehmann, C., Brakch, N., Fischer, J.,
Huber, M., Bertrand, D., and Hohl, D.
(2003). Identification of SLURP-1
as an epidermal neuromodulator
explains the clinical phenotype of
Mal de Meleda. Hum. Mol. Genet. 12,
3017–3024.
Choi, C., Fortin, J., McCarthy, E. V.,
Oksman, L., Kopin, A. S., and Nitabach,
M. N. (2009). Cellular dissection of
circadian peptide signals using genetically encoded membrane-tethered ligands. Curr. Biol. 19, 1167–1175.
Choo, Y. M., Lee, B. H., Lee, K. S., Kim, B. Y.,
Li, J., Kim, J. G., Lee, J. H., Sohn, H. D.,
Nah, S. Y., and Jin, B. R. (2008). Prlynx1, a modulator of nicotinic acetylcholine receptors in the insect. Mol.
Cell. Neurosci. 38, 224–235.
Chou, J. H., Bargmann, C. I., and
Sengupta, P.(2001).The Caenorhabditis
elegans odr-2 gene encodes a novel Ly6-related protein required for olfaction. Genetics 157, 211–224.
Chuang, R. S., Jaffe, H., Cribbs, L., PerezReyes, E., and Swartz, K. J. (1998).
Inhibition of T-type voltage-gated
calcium channels by a new scorpion
toxin. Nat. Neurosci. 1, 668–674.
Couraud, F., Jover, E., Dubois, J. M., and
Rochat, H. (1982). Two types of scorpion receptor sites, one related to the
activation, the other to the inactivation
of the action potential sodium channel. Toxicon 20, 9–16.
Cuthbertson, A., and Indrevoll, B. (2000).
A method for the one-pot regioselective formation of the two disulfide

bonds of [alpha]-conotoxin SI.
Tetrahedron Lett. 41, 3661–3663.
Daly, N. L., Ekberg, J. A., Thomas, L.,
Adams, D. J., Lewis, R. J., and Craik, D. J.
(2004). Structures of muO-conotoxins from Conus marmoreus. Inhibitors
of tetrodotoxin (TTX)-sensitive and
TTX-resistant sodium channels in
mammalian sensory neurons. J. Biol.
Chem. 279, 25774–25782.
Darvas, M., Morsch, M., Racz, I., Ahmadi,
S., Swandulla, D., and Zimmer, A.
(2009). Modulation of the Ca(2+)
conductance of nicotinic acetylcholine receptors by Lypd6. Eur.
Neuropsychopharmacol. 19, 670–681.
Davies, A., Simmons, D., Hale, G.,
Harrison, R., Tighe, H., Lachmann, P.,
and Waldmann, H. (1989). CD59, an
LY-6-like protein expressed in human
lymphoid cells, regulates the action
of the complement membrane attack
complex on homologous cells. J. Exp.
Med. 170, 637–654.
de Nooij-van Dalen, A. G., van
Dongen, G. A. M. S., Smeets, S. J.,
Nieuwenhuis, E. J. C., Stigtervan Walsum, M., Snow, G. B.,
and Brakenhoff, R. H. (2003).
Characterization of the human Ly-6
antigens, the newly annotated member
Ly-6K included, as molecular markers
for head-and-neck squamous cell carcinoma. Int. J. Cancer 103, 768–774.
Dessaud, E., Salaün, D., Gayet, O.,
Chabbert, M., and deLapeyrière,
O. (2006). Identification of lynx2,
a novel member of the ly-6/neurotoxin superfamily, expressed in neuronal subpopulations during mouse
development. Mol. Cell. Neurosci. 31,
232–242.
Diochot, S., Baron, A., Rash, L. D.,
Deval, E., Escoubas, P., Scarzello, S.,
Salinas, M., and Lazdunski, M. (2004).
A new sea anemone peptide, APETx2,
inhibits ASIC3, a major acid-sensitive
channel in sensory neurons. EMBO J.
23, 1516–1525.
Drachman, D. B. (1981). The biology
of myasthenia gravis. Annu. Rev.
Neurosci. 4, 195–225.
Ellison, M., Haberlandt, C., GomezC a s a t i , M . E . , Wa t k i n s , M . ,
Elgoyhen, A. B., McIntosh, J. M.,
and Olivera, B. M. (2006). α-RgIA: a
novel conotoxin that specifically and
potently blocks the α9α10 nAChR.
Biochemistry 45, 1511–1517.
Endo, T., and Tamiya, N. (1991).
Structure–function relationship of
postsynaptic neurotoxins from snake
venoms. In Snake Toxins, A. L. Harvey,
ed. (New York, Pergamon Press),
pp. 165–222.
Fainzilber, M., Hasson, A., Oren, R.,
Burlingame, A. L., Gordon, D.,
Spira, M. E., and Zlotkin, E. (1994).

www.frontiersin.org

New mollusc-specific alphaconotoxins block Aplysia neuronal
acetylcholine receptors. Biochemistry
33, 9523–9529.
Ferber, M., Sporning, A., Jeserich, G.,
DeLaCruz, R., Watkins, M.,
Olivera, B. M., and Terlau, H. (2003).
A novel Conus peptide ligand for
K+ channels. J. Biol. Chem. 278,
2177–2183.
Fontecilla-Camps, J. C., HabersetzerRochat, C., and Rochat, H. (1988).
Orthorhombic crystals and threedimensional structure of the potent
toxin II from the scorpion Androctonus
australis hector. Proc. Natl. Acad. Sci.
U.S.A. 85, 7443–7447.
Fortin, J., Zhu, Y., Choi, C., Beinborn, M.,
Nitabach, M. N., and Kopin, A. S.
(2009). Membrane-tethered ligands
are effective probes for exploring class
B1 G protein-coupled receptor function. Proc. Natl. Acad. Sci. U.S.A. 106,
8049–8054.
Garrido, J. J., Giraud, P., Carlier, E.,
Fernandes, F., Moussif, A., Fache, M.,
Debanne, D., and Dargent, B. (2003).
A targeting motif involved in sodium
channel clustering at the axonal initial
segment. Science 300, 2091–2094.
George, A. L. (2005). Inherited disorders
of voltage-gated sodium channels.
J. Clin. Invest. 115, 1990–1999.
Goldin, A. L. (2001). Resurgence of
sodium channel research. Annu. Rev.
Physiol. 63, 871–894.
Gowd, K. H., Twede, V., Watkins, M.,
Krishnan, K. S., Teichert, R. W.,
Bulaj, G., and Olivera, B. M. (2008).
Conantokin-P, an unusual conantokin
with a long disulfide loop. Toxicon 52,
203–213.
Green, B. D., and Flatt, P. R. (2007).
Incretin hormone mimetics and analogues in diabetes therapeutics. Best
Pract. Res. Clin. Endocrinol. Metab.
21, 497–516.
Han, T. S., Teichert, R. W., Olivera, B.
M., and Bulaj, G. (2008). Conus venoms – a rich source of peptide-based
therapeutics. Curr. Pharm. Des. 14,
2462–2479.
Han, T. S., Zhang, M., Walewska, A.,
Gruszczynski, P., Robertson, C. R.,
Cheatham, T. E., Yoshikami, D.,
Olivera, B. M., and Bulaj, G. (2009).
Structurally minimized mu-conotoxin
analogues as sodium channel blockers: implications for designing
conopeptide-based therapeutics.
Chem. Med. Chem. 4, 406–414.
Hijazi, A., Masson, W., Auge, B., Waltzer,
L., Haenlin, M., and Roch, F. (2009).
Boudin is required for septate junction organisation in Drosophila and
codes for a diffusible protein of the
Ly6 superfamily. Development 136,
2199–2209.

October 2009 | Volume 2 | Article 21 | 8

Holford et al.

Hillyard, D. R., Monje, V. D., Mintz, I. M.,
Bean, B. P., Nadasdi, L., Ramachandran,
J., Miljanich, G., Azimi-Zoonooz, A.,
McIntosh, J. M., and Cruz, L. J. (1992).
A new Conus peptide ligand for mammalian presynaptic Ca2+ channels.
Neuron 9, 69–77.
Hoare, S. R. J. (2005). Mechanisms
of peptide and nonpeptide ligand
binding to Class B G-protein-coupled receptors. Drug Discov. Today
10, 417–427.
Holford, M., Zhang, M., Gowd, K. H.,
Azam, L., Green, B. R., Watkins, M.,
Ownby, J., Yoshikami, D., Bulaj, G.,
and Olivera, B. M. (2009). Pruning
nature: biodiversity-derived discovery of novel sodium channel blocking conotoxins from Conus bullatus.
Toxicon 53, 90–98.
Hruska, M., Ibañez-Tallon, I., and
Nishi, R. (2007). Cell-autonomous
inhibition of alpha 7-containing nicotinic acetylcholine receptors prevents
death of parasympathetic neurons
during development. J. Neurosci. 27,
11501–11509.
Hruska, M., Keefe, J., Wert, D., Tekinay, A.,
Hulce, J., Ibanez-Tallon, I., and Nishi,
R. (2009). Prostate stem cell antigen is
an endogenous lynx1-like prototoxin
that antagonizes alpha7 containing
nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J. Neurosci. (In press).
Hucho, F., Tsetlin, V. I., and Machold, J.
(1996). The emerging three-dimensional structure of a receptor. The
nicotinic acetylcholine receptor. Eur.
J. Biochem. 239, 539–557.
Ibañez-Tallon, I., Miwa, J. M., Wang, H. L.,
Adams, N. C., Crabtree, G. W.,
Sine, S. M., and Heintz, N. (2002).
Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin
lynx1. Neuron 33, 893–903.
Ibañez-Tallon, I., Wen, H., Miwa, J. M.,
Xing, J., Tekinay, A. B., Ono, F.,
Brehm, P., and Heintz, N. (2004).
Tethering naturally occurring peptide
toxins for cell-autonomous modulation of ion channels and receptors in
vivo. Neuron 43, 305–11.
Inchauspe, C. G., Martini, F. J.,
Forsythe, I. D., and Uchitel, O. D.
(2004). Functional compensation of
P/Q by N-type channels blocks shortterm plasticity at the calyx of held
presynaptic terminal. J. Neurosci. 24,
10379–10383.
Jiang, Z., and Zhou, Y. (2006). Using
silico methods predicting ligands for
orphan GPCRs. Curr. Protein Pept. Sci.
7, 459–464.
Klaassen, A., Glykys, J., Maguire, J.,
Labarca, C., Mody, I., and Boulter, J.
(2006). Seizures and enhanced cor-

Frontiers in Molecular Neuroscience

Neuronal regulation using tethered peptides

tical GABAergic inhibition in two
mouse models of human autosomal
dominant nocturnal frontal lobe epilepsy. Proc. Natl. Acad. Sci. U.S.A. 103,
19152–19157.
Léna, C., and Changeux, J. P. (1998).
Allosteric nicotinic receptors, human
pathologies. J. Physiol. 92, 63–74.
Lewis, T. L., Mao, T., Svoboda, K., and
Arnold, D. B. (2009). Myosin-dependent targeting of transmembrane
proteins to neuronal dendrites. Nat.
Neurosci. 12, 568–576.
Lu, B. S., Yu, F., Zhao, D., Huang, P. T.,
and Huang, C. F. (1999). Conopeptides
from Conus striatus and Conus textile by cDNA cloning. Peptides 20,
1139–1144.
Luo, S., Kulak, J. M., Cartier, G. E.,
Jacobsen, R. B., Yoshikami, D.,
Olivera, B. M., and McIntosh, J. M.
(1998). alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic
acetylcholine receptors and nicotineevoked norepinephrine release. J.
Neurosci. 18, 8571–8579.
Lynch, S. S., Cheng, C. M., and Yee, J. L.
(2006). Intrathecal ziconotide
for refractory chronic pain. Ann.
Pharmacother. 40, 1293–1300.
Mallya, M., Campbell, R. D., and
Aguado, B. (2006). Characterization of
the five novel Ly-6 superfamily members encoded in the MHC, and detection of cells expressing their potential
ligands. Protein Sci. 15, 2244–2256.
McIntosh, J. M., Hasson, A., Spira, M. E.,
Gray, W. R., Li, W., Marsh, M., Hillyard,
D. R., and Olivera, B. M. (1995). A new
family of conotoxins that blocks voltage-gated sodium channels. J. Biol.
Chem. 270, 16796–16802.
McIntosh, J. M., Santos, A. D., and
Olivera, B. M. (1999). Conus peptides
targeted to specific nicotinic acetylcholine receptor subtypes. Annu. Rev.
Biochem. 68, 59–88.
Mc In to s h , M . , Cr u z , L . J. ,
Hunkapiller, M. W., Gray, W. R., and
Olivera, B. M. (1982). Isolation and
structure of a peptide toxin from
the marine snail Conus magus. Arch.
Biochem. Biophys. 218, 329–334.
Mebs, D. (1989). Snake venoms: toolbox
of the neurobiologist. Endeavour 13,
157–161.
Miljanich, G. P. (2004). Ziconotide: neuronal calcium channel blocker for
treating severe chronic pain. Curr.
Med. Chem. 11, 3029–3040.
Mintz, I. M., Venema, V. J., Adams, M. E.,
and Bean, B. P. (1991). Inhibition
of N- and L-type Ca2+ channels by
the spider venom toxin omega-AgaIIIA. Proc. Natl. Acad. Sci. U.S.A. 88,
6628–6631.
Mintz, I. M., Venema, V. J., Swiderek, K. M.,
Lee, T. D., Bean, B. P., and Adams,

M. E. (1992). P-type calcium channels
blocked by the spider toxin [omega]Aga-IVA. Nature 355, 827–829.
Miwa, J., Stevens, T., King, S.,
Caldarone, B., Ibaneztallon, I.,
Xiao, C., Fitzsimonds, R., Pavlides, C.,
Lester, H., and Picciotto, M. (2006).
The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival
in vivo. Neuron 51, 587–600.
Miwa, J. M., Ibanez-Tallon, I.,
Crabtree, G. W., Sánchez, R., Sali, A.,
Role, L. W., and Heintz, N. (1999).
lynx1, an endogenous toxin-like
modulator of nicotinic acetylcholine
receptors in the mammalian CNS.
Neuron 23, 105–114.
Munson, M. C., and Barany, G. (1993).
Synthesis of alpha-conotoxin SI, a
bicyclic tridecapeptide amide with
two disulfide bridges: illustration of
novel protection schemes and oxidation strategies. J. Am. Chem. Soc. 115,
10203–10210.
Naranjo, D. (2002). Inhibition of single Shaker K channels by kappaconotoxin-PVIIA. Biophys. J. 82,
3003–3011.
Newcomb, R., Szoke, B., Palma, A.,
Wang, G., Chen, X. H., Hopkins, W.,
Cong, R., Miller, J., Urge, L.,
Tarczy-Hornoch, K., Loo, J. A.,
Dooley, D. J., Nadasdi, L., Tsien, R. W.,
Lemos, J., and Miljanic, G. (1998).
Selective peptide antagonist of the
class E calcium channel from the
venom of the tarantula Hysterocrates
gigas. Biochemistry 37, 15353–15362.
Nicke, A., Loughnan, M. L., Millard, E. L.,
Alewood, P. F., Adams, D. J., Daly, N. L.,
Craik, D. J., and Lewis, R. J. (2003).
Isolation, structure, and activity of
GID, a novel alpha 4/7-conotoxin with
an extended N-terminal sequence.
J. Biol. Chem. 278, 3137–3144.
Nir thanan, S., Charpantier, E.,
Gopalakrishnakone, P., Gwee, M. C. E.,
Khoo, H., Cheah, L., Bertrand, D.,
and Kini, R. M. (2002). Candoxin, a
novel toxin from Bungarus candidus,
is a reversible antagonist of muscle
(alphabetagammadelta) but a poorly
reversible antagonist of neuronal alpha
7 nicotinic acetylcholine receptors.
J. Biol. Chem. 277, 17811–17820.
Nirthanan, S., and Gwee, M. C. E. (2004).
Three-finger alpha-neurotoxins and
the nicotinic acetylcholine receptor,
forty years on. J. Pharmacol. Sci. 94,
1–17.
Norton, R. S., and Olivera, B. M. (2006).
Conotoxins down under. Toxicon 48,
780–798.
Olivera, B. M., McIntosh, J. M., Cruz, L. J.,
Luque, F. A., and Gray, W. R. (1984).
Purification and sequence of a presynaptic peptide toxin from Conus

www.frontiersin.org

geographus venom. Biochemistry 23,
5087–5090.
Ophoff, R. A., Terwindt, G. M.,
Vergouwe, M. N., van Eijk, R.,
Oefner, P. J., Hoffman, S. M.,
Lamerdin, J. E., Mohrenweiser, H. W.,
Bulman, D. E., Ferrari, M., Haan, J.,
Lindhout, D., van Ommen, G. J.,
Hofker, M. H., Ferrari, M. D., and
Frants, R. R. (1996). Familial hemiplegic migraine and episodic ataxia
type-2 are caused by mutations in
the Ca2+ channel gene CACNL1A4.
Cell 87, 543–552.
Pashkov, V. S., Maiorov, V. N., Bystrov, V. F.,
Hoang, A. N., Volkova, T. M., and
Grishin, E. V. (1988). Solution spatial structure of ‘long’ neurotoxin
M9 from the scorpion Buthus eupeus
by 1H-NMR spectroscopy. Biophys.
Chem. 31, 121–131.
Paulick, M. G., and Bertozzi, C. R. (2008).
The glycosylphosphatidylinositol
anchor: a complex membraneanchoring structure for proteins.
Biochemistry 47, 6991–7000.
Phui Yee, J. S., Nanling, G., Afifiyan, F.,
Dong hui, M., Siew Lay, P.,
Armugam, A., and Jeyaseelan, K.
(2004). Snake postsynaptic neurotoxins: gene structure, phylogeny and
applications in research and therapy.
Biochimie 86, 137–149.
Possani, L. D., Becerril, B., Delepierre, M.,
and Tytgat, J. (1999). Scorpion toxins
specific for Na+-channels. Eur. J.
Biochem. 264, 287–300.
Rock, K. L., Reiser, H., Bamezai, A.,
McGrew, J., and Benacerraf, B.
(1989). The LY-6 locus: a multigene
family encoding phosphatidylinositol-anchored membrane proteins
concerned with T-cell activation.
Immunol. Rev. 111, 195–224.
Sekhon, H. S., Song, P., Jia, Y., Lindstrom, J.,
and Spindel, E. R. (2005). Expression
of lynx1 in developing lung and
its modulation by prenatal nicotine exposure. Cell Tissue Res. 320,
287–297.
Shemesh, R., Toporik, A., Levine, Z.,
Hecht, I., Rotman, G., Wool, A.,
Dahary, D., Gofer, E., Kliger, Y.,
Soffer, M. A., Rosenberg, A., Eshel, D.,
and Cohen, Y. (2008). Discovery and
validation of novel peptide agonists for
G-protein-coupled receptors. J. Biol.
Chem. 283, 34643–34649.
Shioda, S., Takenoya, F., Yagi, M., Wang, L.,
Hori, Y., and Kageyama, H. (2008).
Neural networks of several novel
neuropeptides involved in feeding
regulation. Nutrition 24, 848–853.
Shon, K. J., Olivera, B. M., Watkins, M.,
Jacobsen, R. B., Gray, W. R.,
Floresca, C. Z., Cruz, L. J., Hillyard, D. R.,
Brink, A., Terlau, H., and Yoshikami, D.
(1998). mu-Conotoxin PIIIA, a new

October 2009 | Volume 2 | Article 21 | 9

Holford et al.

peptide for discriminating among tetrodotoxin-sensitive Na channel subtypes.
J. Neurosci. 18, 4473–4481.
Sine, S. M., Kreienkamp, H. J., Bren, N.,
Maeda, R., and Taylor, P. (1995).
Molecular dissection of subunit
interfaces in the acetylcholine receptor: identification of determinants
of alpha-conotoxin M1 selectivity.
Neuron 15, 205–211.
Staats, P. S., Yearwood, T., Charapata, S. G.,
Presley, R. W., Wallace, M. S., ByasSmith, M., Fisher, R., Bryce, D. A.,
Mangieri, E. A., Luther, R. R., Mayo,
M., McGuire, D., and Ellis, D. (2004).
Intrathecal ziconotide in the treatment
of refractory pain in patients with cancer or AIDS: a randomized controlled
trial. J. Am. Med. Assoc. 291, 63–70.
Steinlein, O. K., Mulley, J. C., Propping, P.,
Wallace, R. H., Phillips, H. A.,
Sutherland, G. R., Scheffer, I. E., and
Berkovic, S. F. (1995). A missense
mutation in the neuronal nicotinic
acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.
Nat. Genet. 11, 201–203.
Takahashi, E., Ino, M., Miyamoto, N., and
Nagasu, T. (2004). Increased expression of P/Q-type Ca2+ channel
alpha1A subunit mRNA in cerebellum of N-type Ca2+ channel alpha1B
subunit gene-deficient mice. Brain Res.
Mol. Brain Res. 124, 79–87.
Tekinay, A. B., Nong, Y., Miwa, J. M.,
Lieberam, I., Ibanez-Tallon, I.,

Frontiers in Molecular Neuroscience

Neuronal regulation using tethered peptides

Greengard, P., and Heintz, N. (2009).
A role for LYNX2 in anxiety-related
behavior. Proc. Natl. Acad. Sci. U.S.A.
106, 4477–4482.
Terlau, H., and Olivera, B. M. (2004).
Conus venoms: a rich source of novel
ion channel-targeted peptides. Physiol.
Rev. 84, 41–68.
Terlau, H., Shon, K. J., Grilley, M.,
Stocker, M., Stühmer, W., and
Olivera, B. M. (1996). Strategy for
rapid immobilization of prey by a
fish-hunting marine snail. Nature
381, 148–151.
Tottene, A., Conti, R., Fabbro, A.,
Vecchia, D., Shapovalova, M., Santello,
M., van den Maagdenberg, A. M. J.
M., Ferrari, M. D., and Pietrobon, D.
(2009). Enhanced excitatory transmission at cortical synapses as the basis
for facilitated spreading depression
in Ca(v)2.1 knockin migraine mice.
Neuron 61, 762–773.
Tsetlin, V. (1999). Snake venom alphaneurotoxins and other ‘three-finger’
proteins. Eur. J. Biochem. 264,
281–286.
Tsuji, H., Okamoto, K., Matsuzaka, Y.,
Iizuka, H., Tamiya, G., and Inoko, H.
(2003). SLURP-2, a novel member
of the human Ly-6 superfamily that
is up-regulated in psoriasis vulgaris.
Genomics 81, 26–33.
Twede, V. D., Miljanich, G., Olivera, B. M.,
and Bulaj, G. (2009). Neuroprotective
and cardioprotective conopeptides:
an emerging class of drug leads.

Curr. Opin. Drug. Discov. Dev. 12,
231–239.
Ueberheide, B. M., Fenyö, D., Alewood,
P. F., and Chait, B. T. (2009). Rapid
sensitive analysis of cysteine rich
p e p t i d e ve n o m co m p o n e n t s .
Proc. Natl. Acad. Sci. U.S.A. 106,
6910–6915.
Walewska, A., Zhang, M., Skalicky, J. J.,
Yoshikami, D., Olivera, B. M., and
Bulaj, G. (2009). Integrated oxidative folding of cysteine/selenocysteine
containing peptides: improving
chemical synthesis of conotoxins.
Angew. Chem. Int. Ed. Engl. 48,
2221–2224.
West, P. J., Bulaj, G., Garrett, J. E., Olivera,
B. M., and Yoshikami, D. (2002). Muconotoxin SmIIIA, a potent inhibitor of tetrodotoxin-resistant sodium
channels in amphibian sympathetic
and sensory neurons. Biochemistry 41,
15388–15393.
Wu, Y., Cao, G., Pavlicek, B., Luo, X., and
Nitabach, M. N. (2008). Phase coupling of a circadian neuropeptide with
rest/activity rhythms detected using
a membrane-tethered spider toxin.
PLoS Biol. 6, e273. doi: 10.1371/journal.pbio.0060273.
Xiao, Y., and Liang, S. (2003). Inhibition
of neuronal tetrodotoxin-sensitive
Na+ channels by two spider toxins:
hainantoxin-III and hainantoxin-IV.
Eur. J. Pharmacol. 477, 1–7.
Zhang, M., Fiedler, B., Green, B. R.,
Catlin, P., Watkins, M., Garrett, J. E.,

www.frontiersin.org

Smith, B. J., Yoshikami, D., Olivera, B.
M., and Bulaj, G. (2006). Structural
and functional diversities among
µ-conotoxins targeting TTX-resistant sodium channels. Biochemistry
45, 3723–3732.
Zuo, X., and Ji, Y. (2004). Molecular mechanism of scorpion neurotoxins acting
on sodium channels: insight into their
diverse selectivity. Mol. Neurobiol. 30,
265–278.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any commercial or financial relationships that
could be construed as a potential conflict
of interest.
Received: 03 July 2009; paper pending published: 17 July 2009; accepted:
10 October 2009; published online: 30
October 2009.
Citation: Holford M, Auer S, Laqua M
and Ibañez-Tallon I (2009) Manipulating
neuronal circuits with endogenous and
recombinant cell-surface tethered modulators. Front. Mol. Neurosci. 2:21. doi:
10.3389/neuro.02.021.2009
Copyright © 2009 Holford, Auer, Laqua
and Ibañez-Tallon. This is an open-access
article subject to an exclusive license agreement between the authors and the Frontiers
Research Foundation, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
authors and source are credited.

October 2009 | Volume 2 | Article 21 | 10

